BioLife’s CryoCase wins award for tackling frozen therapy bag failures

robot
Abstract generation in progress

BioLife Solutions (NASDAQ: BLFS) has won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system designed to prevent failures common with flexible cryobags in cell and gene therapy manufacturing. Launched in 2025, CryoCase provides reinforced structural protection during freezing, liquid nitrogen storage, and distribution, addressing a significant industry need for improved containment and visual inspection of frozen biologic materials. This award validates the product’s importance as CGT programs move towards commercialization and regulatory scrutiny increases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin